Krystal Biotech, Inc.

NASDAQ:KRYS

Biotechnology

Healthcare
$315.34 +5.66%

+$18.29 today

Market cap
$9.34B
Beta
0.53
P/E (TTM)
44.5
EPS (TTM)
$7.68
52W Low $130.17High $347.67

Volume 0.35M

Average 0.29M

KRYS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Krystal Biotech, Inc.NASDAQ: KRYS

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables grows, but more slowly than its trailing trend

Q2 FY2026 accounts receivables of $11.97M (cash outflow) rose 46.4% year over year, behind the +233.4% change in trailing-twelve-month accounts receivables.

Context

  • Accounts receivables amounted to 5.7% of revenue in FY2025, down 15.9 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +46.4% toward the trailing-twelve-month pace of +233.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$11.97M-20743.1% QoQ
Last fiscal yearDec 2025
-$22.12M-64.7% YoY
LTMJun 2026
-$27.35M+233.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.4%——
1 year-64.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(22.12M) USD
Year-over-year change
+64.7%

Accounts Receivables vs competitors

How KRYS compares with its peers on the latest reported figures

  • KRYS's LTM Jun 2026 accounts receivables of $27.35M is the largest of the 6 companies compared; the peer median is $0.
  • Its year-over-year change of +233.4% is the 2nd highest of 4, against a peer median of -178.8%.
  • Accounts receivables amounts to 6.2% of revenue for KRYS, versus a peer median of 16.3%.
KRYS Competitors Peer median
Accounts Receivables for KRYS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KRYSKrystal Biotech, Inc.LTM Jun 2026$27.35M +233.4%—6.2%
MGTXMeiraGTx Holdings plcLTM Mar 2026$13.03M -178.8%—16.3%
RGNXREGENXBIO Inc.LTM Mar 2026$9.02M +328.9%—10.3%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$5.09M -985.6%—35.0%
SANASana Biotechnology, Inc.LTM Mar 2026$0 ———
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$0 ———
Peer median (excluding KRYS) $0-178.8%—16.3%

Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(69.57M)(139.98M)10.93M89.16M204.83M
Depreciation & Amortization2.77M4.05M5.01M6.71M6.55M
Deferred Income Tax0000(22.85M)
Stock-Based Compensation15.32M33.23M39.93M49.13M54.51M
Change in Working Capital2.05M2.81M(37.88M)(14.46M)(36.42M)
Accounts Receivables00(42.04M)(62.71M)(22.12M)
Inventory00(4.48M)(11.91M)(6.29M)
Accounts Payables712K(1.25M)(101K)1.01M826K
Other Working Capital1.34M4.07M8.73M59.15M(8.84M)
Other Non-Cash Items1.49M(690K)(106.79M)(7.12M)(5.77M)
Operating Cash Flow(47.94M)(100.57M)(88.8M)123.42M200.87M
Capital Expenditures(68.34M)(52.98M)(11.8M)(4.24M)(11.95M)
Acquisitions (Net)0000435K
Purchases of Investments(190.46M)(318.78M)(508.78M)(457.74M)(422.54M)
Sales of Investments32.03M257.68M503.21M298.54M375.64M
Other Investing Activities00100M00
Investing Cash Flow(226.77M)(114.08M)82.64M(163.44M)(58.42M)
Debt Repayment00000
Common Stock Issued355.65M36M203.5M32.4M22.66M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(7.96M)(649K)(749K)(5.39M)(13.96M)
Financing Cash Flow347.69M35.35M202.75M27.01M8.71M
Effect of Forex Changes0(41K)(156K)(458K)286K
Net Change in Cash72.98M(179.35M)196.43M(13.46M)151.44M
Free Cash Flow(116.27M)(153.55M)(100.6M)119.18M188.91M

Krystal Biotech, Inc.

NASDAQ:KRYS

Intrinsic Alpha fair value

Locked

Current Price

$315.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.